Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can coffee lovers with AF keep their daily cup? a trial investigates

NCT ID NCT07738523

Disease control Sponsor: Hospital Universitario Getafe Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial asks whether people with permanent atrial fibrillation (AF) can continue drinking caffeinated coffee without worsening their heart rate control. Half of the participants will keep their usual coffee habit, while the other half will switch to decaf for a month, then swap. Researchers will measure each person's average heart rate over 24 hours to see if coffee makes a meaningful difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
caffeine (via regular coffee consumption)
What this could lead to
If moderate coffee intake proves non-inferior to abstinence, people with permanent atrial fibrillation may not need to give up their daily cup.
What could go wrong
The trial is small and open-label, relying on self-reported caffeine intake. Individual differences in caffeine metabolism could affect results, and the findings may not apply to all AF patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Permanent atrial fibrillation diagnosed for more than 3 months. * Stable rate-control status, defined as a resting heart rate \<110 bpm without changes in rate-control medication during the previous 2 months. * Habitual caffeine consumption (≥1 cup/day of caffeinated coffee). * Willingness to participate in the study, including acceptance of complete caffeine abstinence for up to two months if assigned to the abstinence arm. Exclusion Criteria: * Age \<18 years or \>80 years. * Previous diagnosis of cognitive impairment or dementia. * Legal incapacity or inability to provide informed consent. * Inability to understand or complete quality-of-life questionnaires. * Presence of a cardiac implantable electronic device with pacing capability (pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy device). * Previous successful atrioventricular node ablation. * Decompensated heart failure (New York Heart Association class III-IV) or hospitalization for heart failure within the previous 3 months. * Acute coronary syndrome within the previous 3 months. * Stroke within the previous 3 months. * Cardiac surgery within the previous 3 months. * Severe unrepaired valvular heart disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF) Caffeine abuse Coffee consumption Permanent atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Getafe University Hospital

    RECRUITING

    Getafe, Madrid, 28905, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.